Addus HomeCare Corporation Common Stock (ADUS)

FairStock Score: 74/100 — STEADY

Key Financials

Strengths

• Generates $72 million in annual free cash flow (4.1% yield on market cap)
• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Conservative balance sheet with debt-to-equity of just 0.16, providing financial flexibility
• Revenue growth of 25.6% demonstrates strong top-line momentum
• FairStock composite score of 74/100 places it in the top tier across value, quality, and momentum factors

AI Analysis

Addus HomeCare Corporation Common Stock is a micro-cap healthcare company valued at $1.8 billion. The business generates $1.4 billion in annual revenue with a 2.1% net margin and $72 million in free cash flow. From a quality standpoint, Addus shows solid Piotroski F-Score of 7/9 and healthy Altman Z-Score of 3.9. On valuation, the stock is reasonably priced at 18.1x earnings, with trades above its Graham Number with a negative 13% margin. Growth dynamics show revenue growing at 25.6% and profit growth of 52.5%. Our composite FairStock Score of 74/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Addus's 26% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $72 million in annual free cash flow (4.1% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer